Genelux Investor Presentation Deck

Intellectual Property: Market Exclusivity & Freedom to Operate GENELUX 0-0-0-0 + Patent Portfolio: 33 issued patents; 7 pending Olvi-Vec covered by Composition of Matter (2031) and Manufacturing (2038) Olvi-Vec: Worldwide operating freedom; No third-party royalties due Long Duration of Regulatory / Marketing Exclusivity Strong IP & Regulatory Designations 28

View entire presentation